Invasive pulmonary aspergillosis (IPA) is a life-threatening form of fungal infection, primarily in immunocompromised patients and associated with significant mortality. Diagnostic procedures are often invasive and/or time consuming and existing antifungals can be constrained by dose-limiting toxicity and drug interaction. In this study, we modified triacetylfusarinine C (TAFC), the main siderophore produced by the opportunistic pathogen Aspergillus fumigatus (A. fumigatus), with antifungal molecules to perform antifungal susceptibility tests and molecular imaging. A variation of small organic molecules (eflornithine, fludioxonil, thiomersal, fluoroorotic acid (FOA), cyanine 5 (Cy5) with antifungal activity were coupled to diacetylfusarinine C (DAFC), resulting in a "Trojan horse" to deliver antifungal compounds specifically into A. fumigatus hyphae by the major facilitator transporter MirB. Radioactive labeling with gallium-68 allowed us to perform in vitro characterization (distribution coefficient, stability, uptake assay) as well as biodistribution experiments and PET/CT imaging in an IPA rat infection model. Compounds chelated with stable gallium were used for antifungal susceptibility tests. [Ga]DAFC-fludioxonil, -FOA, and -Cy5 revealed a MirB-dependent active uptake with fungal growth inhibition at 16 µg/mL after 24 h. Visualization of an A. fumigatus infection in lungs of a rat was possible with gallium-68-labeled compounds using PET/CT. Heterogeneous biodistribution patterns revealed the immense influence of the antifungal moiety conjugated to DAFC. Overall, novel antifungal siderophore conjugates with promising fungal growth inhibition and the possibility to perform PET imaging combine both therapeutic and diagnostic potential in a theranostic compound for IPA caused by A. fumigatus.

Department of Nuclear Medicine Medical University Innsbruck A 6020 Innsbruck Austria

Institute of Hygiene and Medical Microbiology Medical University of Innsbruck A 6020 Innsbruck Austria

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc 77200 Olomouc Czech Republic

Institute of Molecular Biology Medical University of Innsbruck A 6020 Innsbruck Austria

Institute of Pharmacy Pharmaceutical Chemistry University of Innsbruck A 6020 Innsbruck Austria

See more in PubMed

Bongomin F., Gago S., Oladele R., Denning D. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J. Fungi. 2017;3:57. doi: 10.3390/jof3040057. PubMed DOI PMC

Brown G.D., Denning D.W., Gow N.A.R., Levitz S.M., Netea M.G., White T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012;4:rv13–rv165. doi: 10.1126/scitranslmed.3004404. PubMed DOI

Jenks J., Hoenigl M. Treatment of Aspergillosis. J. Fungi. 2018;4:98. doi: 10.3390/jof4030098. PubMed DOI PMC

Latgé J.-P. Aspergillus fumigatus and Aspergillosis. Clin. Microbiol. Rev. 1999;12:310–350. doi: 10.1128/CMR.12.2.310. PubMed DOI PMC

Ullmann A.J., Aguado J.M., Arikan-Akdagli S., Denning D.W., Groll A.H., Lagrou K., Lass-Flörl C., Lewis R.E., Munoz P., Verweij P.E., et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 2018;24:e1–e38. doi: 10.1016/j.cmi.2018.01.002. PubMed DOI

Moura S., Cerqueira L., Almeida A. Invasive pulmonary aspergillosis: Current diagnostic methodologies and a new molecular approach. Eur. J. Clin. Microbiol. Infect. Dis. 2018;37:1393–1403. doi: 10.1007/s10096-018-3251-5. PubMed DOI

Van Daele R., Spriet I., Wauters J., Maertens J., Mercier T., Van Hecke S., Brüggemann R. Antifungal drugs: What brings the future? Med. Mycol. 2019;57:S328–S343. doi: 10.1093/mmy/myz012. PubMed DOI

Verweij P.E., Lucas J.A., Arendrup M.C., Bowyer P., Brinkmann A.J.F., Denning D.W., Dyer P.S., Fisher M.C., Geenen P.L., Gisi U., et al. The one health problem of azole resistance in Aspergillus fumigatus: Current insights and future research agenda. Fungal Biol. Rev. 2020;34:202–214. doi: 10.1016/j.fbr.2020.10.003. DOI

Nairz M., Weiss G. Iron in infection and immunity. Mol. Asp. Med. 2020;75:100864. doi: 10.1016/j.mam.2020.100864. PubMed DOI

Haas H. Iron—A Key Nexus in the Virulence of Aspergillus fumigatus. Front. Microbiol. 2012;3:1–10. doi: 10.3389/fmicb.2012.00028. PubMed DOI PMC

Schrettl M., Bignell E., Kragl C., Joechl C., Rogers T., Arst H.N., Haynes K., Haas H. Siderophore Biosynthesis But Not Reductive Iron Assimilation Is Essential for Aspergillus fumigatus Virulence. J. Exp. Med. 2004;200:1213–1219. doi: 10.1084/jem.20041242. PubMed DOI PMC

Haas H. Fungal siderophore metabolism with a focus on Aspergillus fumigatus. Nat. Prod. Rep. 2014;31:1266–1276. doi: 10.1039/C4NP00071D. PubMed DOI PMC

Haas H., Schoeser M., Lesuisse E., Ernst J.F., Parson W., Abt B., Winkelmann G., Oberegger H. Characterization of the Aspergillus nidulans transporters for the siderophores enterobactin and triacetylfusarinine C. Biochem. J. 2003;371:505–513. doi: 10.1042/bj20021685. PubMed DOI PMC

Petrik M., Haas H., Laverman P., Schrettl M., Franssen G.M., Blatzer M., Decristoforo C. 68Ga-Triacetylfusarinine C and 68Ga-Ferrioxamine E for Aspergillus Infection Imaging: Uptake Specificity in Various Microorganisms. Mol. Imaging Biol. 2014;16:102–108. doi: 10.1007/s11307-013-0654-7. PubMed DOI PMC

Raymond-Bouchard I., Carroll C.S., Nesbitt J.R., Henry K.A., Pinto L.J., Moinzadeh M., Scott J.K., Moore M.M. Structural Requirements for the Activity of the MirB Ferrisiderophore Transporter of Aspergillus fumigatus. Eukaryot. Cell. 2012;11:1333–1344. doi: 10.1128/EC.00159-12. PubMed DOI PMC

Petrik M., Franssen G.M., Haas H., Laverman P., Hörtnagl C., Schrettl M., Helbok A., Lass-Flörl C., Decristoforo C. Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. Eur. J. Nucl. Med. Mol. Imaging. 2012;39:1175–1183. doi: 10.1007/s00259-012-2110-3. PubMed DOI PMC

Kaeopookum P., Summer D., Pfister J., Orasch T., Lechner B.E., Petrik M., Novy Z., Matuszczak B., Rangger C., Haas H., et al. Modifying the Siderophore Triacetylfusarinine C for Molecular Imaging of Fungal Infection. Mol. Imaging Biol. 2019;21:1097–1106. doi: 10.1007/s11307-019-01325-6. PubMed DOI PMC

Pfister J., Lichius A., Summer D., Haas H., Kanagasundaram T., Kopka K., Decristoforo C. Live-cell imaging with Aspergillus fumigatus-specific fluorescent siderophore conjugates. Sci. Rep. 2020;10:15519. doi: 10.1038/s41598-020-72452-2. PubMed DOI PMC

Pfister J., Summer D., Petrik M., Khoylou M., Lichius A., Kaeopookum P., Kochinke L., Orasch T., Haas H., Decristoforo C., et al. Hybrid Imaging of Aspergillus fumigatus Pulmonary Infection with Fluorescent, 68Ga-Labelled Siderophores. Biomolecules. 2020;10:168. doi: 10.3390/biom10020168. PubMed DOI PMC

Cardenas M.E., Cruz M.C., Del Poeta M., Chung N., Perfect J.R., Heitman J. Antifungal Activities of Antineoplastic Agents:Saccharomyces cerevisiae as a Model System To Study Drug Action. Clin. Microbiol. Rev. 1999;12:583–611. doi: 10.1128/CMR.12.4.583. PubMed DOI PMC

Carmina E. Topical Eflornithine. Am. J. Clin. Dermatol. 2001;2:202. doi: 10.2165/00128071-200102030-00011. PubMed DOI

Levin V.A., Ictech S.E., Hess K.R. Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018;7:CNS16. doi: 10.2217/cns-2017-0031. PubMed DOI PMC

Kuemmerle A., Schmid C., Kande V., Mutombo W., Ilunga M., Lumpungu I., Mutanda S., Nganzobo P., Ngolo D., Kisala M., et al. Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo. PLoS Negl. Trop. Dis. 2020;14:e0008028. doi: 10.1371/journal.pntd.0008028. PubMed DOI PMC

Burri C., Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res. 2003;90:S49–S52. doi: 10.1007/s00436-002-0766-5. PubMed DOI

Beckmann N., Schafferer L., Schrettl M., Binder U., Talasz H., Lindner H., Haas H. Characterization of the Link between Ornithine, Arginine, Polyamine and Siderophore Metabolism in Aspergillus fumigatus. PLoS ONE. 2013;8:e67426. doi: 10.1371/journal.pone.0067426. PubMed DOI PMC

Boeke J.D., La Croute F., Fink G.R. A positive selection for mutants lacking orotidine-5′-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Mol. Gen. Genet. MGG. 1984;197:345–346. doi: 10.1007/BF00330984. PubMed DOI

Kilani J., Fillinger S. Phenylpyrroles: 30 Years, Two Molecules and (Nearly) No Resistance. Front. Microbiol. 2016;7:1–10. doi: 10.3389/fmicb.2016.02014. PubMed DOI PMC

Brandhorst T.T., Klein B.S. Uncertainty surrounding the mechanism and safety of the post-harvest fungicide fludioxonil. Food Chem. Toxicol. 2019;123:561–565. doi: 10.1016/j.fct.2018.11.037. PubMed DOI PMC

Bigham M., Copes R. Thiomersal in vaccines: Balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf. 2005;28:89–101. doi: 10.2165/00002018-200528020-00001. PubMed DOI

Clements C.J. The evidence for the safety of thiomersal in newborn and infant vaccines. Vaccine. 2004;22:1854–1861. doi: 10.1016/j.vaccine.2003.11.017. PubMed DOI

Magos L., Clarkson T.W. Overview of the clinical toxicity of mercury. Ann. Clin. Biochem. 2006;43:257–268. doi: 10.1258/000456306777695654. PubMed DOI

Zhai C., Summer D., Rangger C., Haas H., Haubner R., Decristoforo C. Fusarinine C, a novel siderophore-based bifunctional chelator for radiolabeling with Gallium-68. J. Label. Compd. Radiopharm. 2015;58:209–214. doi: 10.1002/jlcr.3286. PubMed DOI PMC

Pontecorvo G., Roper J.A., Chemmons L.M., Macdonald K.D., Bufton A.W.J. The Genetics of Aspergillus nidulans. Adv. Genet. 1953;5:141–238. PubMed

Pfister J., Bata R., Hubmann I., Hörmann A.A., Gsaller F., Haas H., Decristoforo C. Siderophore Scaffold as Carrier for Antifungal Peptides in Therapy of Aspergillus Fumigatus Infections. J. Fungi. 2020;6:367. doi: 10.3390/jof6040367. PubMed DOI PMC

Ocak M., Helbok A., Rangger C., Peitl P.K., Nock B.A., Morelli G., Eek A., Sosabowski J.K., Breeman W.A.P., Reubi J.C., et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:1426–1435. doi: 10.1007/s00259-011-1818-9. PubMed DOI

Skriba A., Pluhacek T., Palyzova A., Novy Z., Lemr K., Hajduch M., Petrik M., Havlicek V. Early and Non-invasive Diagnosis of Aspergillosis Revealed by Infection Kinetics Monitored in a Rat Model. Front. Microbiol. 2018;9:1–7. doi: 10.3389/fmicb.2018.02356. PubMed DOI PMC

Schrettl M., Kim H.S., Eisendle M., Kragl C., Nierman W.C., Heinekamp T., Werner E.R., Jacobsen I., Illmer P., Yi H., et al. SreA-mediated iron regulation in Aspergillus fumigatus. Mol. Microbiol. 2008;70:27–43. doi: 10.1111/j.1365-2958.2008.06376.x. PubMed DOI PMC

Bastos R.W., Rossato L., Valero C., Lagrou K., Colombo A.L., Goldman G.H. Potential of Gallium as an Antifungal Agent. Front. Cell. Infect. Microbiol. 2019;9:1–11. doi: 10.3389/fcimb.2019.00414. PubMed DOI PMC

Miethke M., Marahiel M.A. Siderophore-based iron acquisition and pathogen control. Microbiol. Mol. Biol. Rev. 2007;71:413–451. doi: 10.1128/MMBR.00012-07. PubMed DOI PMC

Braun V., Pramanik A., Gwinner T., Köberle M., Bohn E. Sideromycins: Tools and antibiotics. BioMetals. 2009;22:3–13. doi: 10.1007/s10534-008-9199-7. PubMed DOI PMC

Mislin G.L.A., Schalk I.J. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics. 2014;6:408–420. doi: 10.1039/C3MT00359K. PubMed DOI

Gumienna-Kontecka E., Carver P.L. Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic. Volume 19. De Gruyter; Berlin, Germany: 2019. Building a Trojan Horse: Siderophore-Drug Conjugates for the Treatment of Infectious Diseases; pp. 331–358. PubMed

Al Shaer D., Al Musaimi O., de la Torre B.G., Albericio F. Hydroxamate siderophores: Natural occurrence, chemical synthesis, iron binding affinity and use as Trojan horses against pathogens. Eur. J. Med. Chem. 2020;208:112791. doi: 10.1016/j.ejmech.2020.112791. PubMed DOI

Dietl A.-M., Misslinger M., Aguiar M.M., Ivashov V., Teis D., Pfister J., Decristoforo C., Hermann M., Sullivan S.M., Smith L.R., et al. The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397. Antimicrob. Agents Chemother. 2019;63:1–13. doi: 10.1128/AAC.00807-19. PubMed DOI PMC

Chitambar C.R. Medical Applications and Toxicities of Gallium Compounds. Int. J. Environ. Res. Public Health. 2010;7:2337–2361. doi: 10.3390/ijerph7052337. PubMed DOI PMC

Chitambar C.R. Gallium and its competing roles with iron in biological systems. Biochim. Biophys. Acta Mol. Cell Res. 2016;1863:2044–2053. doi: 10.1016/j.bbamcr.2016.04.027. PubMed DOI

Goss C.H., Kaneko Y., Khuu L., Anderson G.D., Ravishankar S., Aitken M.L., Lechtzin N., Zhou G., Czyz D.M., McLean K., et al. Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. Sci. Transl. Med. 2018;10:eaat7520. doi: 10.1126/scitranslmed.aat7520. PubMed DOI PMC

Ghosh A., Ghosh M., Niu C., Malouin F., Moellmann U., Miller M.J. Iron transport-mediated drug delivery using mixed-ligand siderophore- β-lactam conjugates. Chem. Biol. 1996;3:1011–1019. doi: 10.1016/S1074-5521(96)90167-2. PubMed DOI

Miller M.J., Zhu H., Xu Y., Wu C., Walz A.J., Vergne A., Roosenberg J.M., Moraski G., Minnick A.A., McKee-Dolence J., et al. Utilization of microbial iron assimilation processes for the development of new antibiotics and inspiration for the design of new anticancer agents. BioMetals. 2009;22:61–75. doi: 10.1007/s10534-008-9185-0. PubMed DOI PMC

Wencewicz T.A., Long T.E., Möllmann U., Miller M.J. Trihydroxamate Siderophore–Fluoroquinolone Conjugates Are Selective Sideromycin Antibiotics that Target Staphylococcus aureus. Bioconjug. Chem. 2013;24:473–486. doi: 10.1021/bc300610f. PubMed DOI PMC

Neumann W., Sassone-Corsi M., Raffatellu M., Nolan E.M. Esterase-Catalyzed Siderophore Hydrolysis Activates an Enterobactin–Ciprofloxacin Conjugate and Confers Targeted Antibacterial Activity. J. Am. Chem. Soc. 2018;140:5193–5201. doi: 10.1021/jacs.8b01042. PubMed DOI PMC

Pandey A., Savino C., Ahn S.H., Yang Z., Van Lanen S.G., Boros E. Theranostic Gallium Siderophore Ciprofloxacin Conjugate with Broad Spectrum Antibiotic Potency. J. Med. Chem. 2019;62:9947–9960. doi: 10.1021/acs.jmedchem.9b01388. PubMed DOI PMC

Glassman P.M., Muzykantov V.R. Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. J. Pharmacol. Exp. Ther. 2019;370:570–580. doi: 10.1124/jpet.119.257113. PubMed DOI PMC

Petrik M., Haas H., Dobrozemsky G., Lass-Florl C., Helbok A., Blatzer M., Dietrich H., Decristoforo C. 68Ga-Siderophores for PET Imaging of Invasive Pulmonary Aspergillosis: Proof of Principle. J. Nucl. Med. 2010;51:639–645. doi: 10.2967/jnumed.109.072462. PubMed DOI PMC

Henneberg S., Hasenberg A., Maurer A., Neumann F., Bornemann L., Gonzalez-Menendez I., Kraus A., Hasenberg M., Thornton C.R., Pichler B.J., et al. Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during antifungal azole treatment. Nat. Commun. 2021;12:1707. doi: 10.1038/s41467-021-21965-z. PubMed DOI PMC

Ferreira K., Hu H.Y., Fetz V., Prochnow H., Rais B., Müller P.P., Brönstrup M. Multivalent Siderophore–DOTAM Conjugates as Theranostics for Imaging and Treatment of Bacterial Infections. Angew. Chem. Int. Ed. 2017;56:8272–8276. doi: 10.1002/anie.201701358. PubMed DOI

Radiotracer Development for Fungal-Specific Imaging: Past, Present, and Future

Desferrioxamine B-Mediated Pre-Clinical In Vivo Imaging of Infection by the Mold Fungus Aspergillus fumigatus